z-logo
Premium
Melanoma never says die
Author(s) -
Haass Nikolas K.,
Schumacher Udo
Publication year - 2014
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.12400
Subject(s) - melanoma , apoptosis , medicine , cancer research , drug resistance , drug , pharmacology , biology , genetics
Drug resistance in melanoma is commonly attributed to ineffective apoptotic pathways. Targeting apoptosis regulators is thus considered a promising approach to sensitizing melanoma to therapy. In the previous issue of Experimental Dermatology, Plötz and Eberle discuss the role that apoptosis plays in melanoma progression and drug resistance and the utility of apoptosis‐inducing BH 3‐mimetics as targeted therapy. There are a number of compounds in clinical development and the field seems close to translating recent findings into benefits for patients with melanoma. Thus, this viewpoint is timely and achieves a valuable summary of the current state of apoptosis‐inducing therapy of melanoma.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here